Branched worm-like nanoparticles featured with programmed drug release for synergistic castration-resistant prostate cancer therapy
Co-delivery systems with programmed release of combined drugs are of great value for combination cancer therapy. However, design of such co-delivery systems for potent synergistic cancer therapy is still a great challenge. In the present work, dimethylcurcumin (DMC) and docetaxel (DTX) co-loaded bra...
Gespeichert in:
| Veröffentlicht in: | Journal of materials science 2020-06, Vol.55 (16), p.6992-7008 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7008 |
|---|---|
| container_issue | 16 |
| container_start_page | 6992 |
| container_title | Journal of materials science |
| container_volume | 55 |
| creator | Hu, Hang Wang, Chong Zhang, Rong Xiao, Chen Lai, Chao Li, Zifu Xu, Defeng |
| description | Co-delivery systems with programmed release of combined drugs are of great value for combination cancer therapy. However, design of such co-delivery systems for potent synergistic cancer therapy is still a great challenge. In the present work, dimethylcurcumin (DMC) and docetaxel (DTX) co-loaded branched worm-like nanoparticles (NPs) with programmed release of DMC and DTX were developed for potent synergistic castration-resistant prostate cancer (CRPC) therapy. (2-Hydroxypropyl)-β-cyclodextrin-retinoic acid (HP-β-CD-RA) conjugates with different molar ratios of RA to HP-β-CD were synthesized and used for the preparation of DMC and DTX co-loaded NPs. The as-prepared DMC and DTX co-loaded NPs (
D
h
170–190 nm) have branched worm-like morphologies, and DMC/DTX@HP-β-CD-RA
3.0
NPs show the highest drug loading content and encapsulation efficiency. DMC/DTX@HP-β-CD-RA
3.0
NPs exhibit programmed drug release patterns with DTX released much faster than DMC, which could be ascribed to the difference between DMC and DTX in the interaction with HP-β-CD-RA
3.0
as analyzed by molecular simulation, phase solubility method, and fluorescence spectra. DMC/DTX@HP-β-CD-RA
3.0
NPs exhibit enhanced cellular uptake as compared to DMC/DTX. Mechanism dissection reveals that the cellular uptake of DMC/DTX@HP-β-CD-RA
3.0
NPs is energy-dependent in which macropinocytosis and clathrin- and caveolae-independent endocytosis pathways are involved. Benefited from their enhanced cellular uptake and programmed drug release, DMC/DTX@HP-β-CD-RA
3.0
NPs exhibit significantly enhanced antitumor effect as compared to DMC/DTX. Such mechanisms for potent synergistic antitumor effect, by enhancing cellular uptake of DMC and DTX together with programmed drug release, may provide new therapeutic options for CRPC. |
| doi_str_mv | 10.1007/s10853-020-04495-9 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2375659355</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A617043635</galeid><sourcerecordid>A617043635</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-db7272aaf0fb22d96cef0ce7b34e2093431ca17fa6b867754c6189bc3e9c67203</originalsourceid><addsrcrecordid>eNp9kUuLFDEURgtRsB39A64KXLnIePOoStdyHHwMDAg-1iGVuqnOWJVqb1KMvfaPm7aFoUEkiyQ35-T1VdVLDpccQL9JHLaNZCCAgVJdw7pH1YY3WjK1Bfm42gAIwYRq-dPqWUp3ANBowTfVr7dko9vhUN8vNLMpfMc62rjsLeXgJky1R5tXOgIh7-o9LSPZeS7zgdaxJpzQJqz9QnU6RKQxpCLWzqZMNoclMsJUajbmo1wGGctqdEh13iHZ_eF59cTbKeGLv_1F9e39u6_XH9ntpw8311e3zCkBmQ29FlpY68H3Qgxd69CDQ91LhQI6qSR3lmtv237bat0o1_Jt1zuJnWu1AHlRvTrtW-7xY8WUzd2yUixHGiF10zadbJoHarQTmhD9Uh7i5pCcuWq5BiVbeaQu_0GVNuAc3BLRh1I_E16fCYXJ-DOPdk3J3Hz5fM6KE-vKhyVCb_YUZksHw8Ec8zanvE3J2_zJ23RFkicpFTiOSA-v-4_1G1Vnrto</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2375659355</pqid></control><display><type>article</type><title>Branched worm-like nanoparticles featured with programmed drug release for synergistic castration-resistant prostate cancer therapy</title><source>Springer Nature - Complete Springer Journals</source><creator>Hu, Hang ; Wang, Chong ; Zhang, Rong ; Xiao, Chen ; Lai, Chao ; Li, Zifu ; Xu, Defeng</creator><creatorcontrib>Hu, Hang ; Wang, Chong ; Zhang, Rong ; Xiao, Chen ; Lai, Chao ; Li, Zifu ; Xu, Defeng</creatorcontrib><description>Co-delivery systems with programmed release of combined drugs are of great value for combination cancer therapy. However, design of such co-delivery systems for potent synergistic cancer therapy is still a great challenge. In the present work, dimethylcurcumin (DMC) and docetaxel (DTX) co-loaded branched worm-like nanoparticles (NPs) with programmed release of DMC and DTX were developed for potent synergistic castration-resistant prostate cancer (CRPC) therapy. (2-Hydroxypropyl)-β-cyclodextrin-retinoic acid (HP-β-CD-RA) conjugates with different molar ratios of RA to HP-β-CD were synthesized and used for the preparation of DMC and DTX co-loaded NPs. The as-prepared DMC and DTX co-loaded NPs (
D
h
170–190 nm) have branched worm-like morphologies, and DMC/DTX@HP-β-CD-RA
3.0
NPs show the highest drug loading content and encapsulation efficiency. DMC/DTX@HP-β-CD-RA
3.0
NPs exhibit programmed drug release patterns with DTX released much faster than DMC, which could be ascribed to the difference between DMC and DTX in the interaction with HP-β-CD-RA
3.0
as analyzed by molecular simulation, phase solubility method, and fluorescence spectra. DMC/DTX@HP-β-CD-RA
3.0
NPs exhibit enhanced cellular uptake as compared to DMC/DTX. Mechanism dissection reveals that the cellular uptake of DMC/DTX@HP-β-CD-RA
3.0
NPs is energy-dependent in which macropinocytosis and clathrin- and caveolae-independent endocytosis pathways are involved. Benefited from their enhanced cellular uptake and programmed drug release, DMC/DTX@HP-β-CD-RA
3.0
NPs exhibit significantly enhanced antitumor effect as compared to DMC/DTX. Such mechanisms for potent synergistic antitumor effect, by enhancing cellular uptake of DMC and DTX together with programmed drug release, may provide new therapeutic options for CRPC.</description><identifier>ISSN: 0022-2461</identifier><identifier>EISSN: 1573-4803</identifier><identifier>DOI: 10.1007/s10853-020-04495-9</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Anticancer properties ; Cancer therapies ; Characterization and Evaluation of Materials ; Chemistry and Materials Science ; Classical Mechanics ; Crystallography and Scattering Methods ; Cyclodextrins ; Drug delivery systems ; Fluorescence ; Health aspects ; Materials for Life Sciences ; Materials Science ; Morphology ; Nanoparticles ; Polymer Sciences ; Prostate cancer ; Retinoic acid ; Solid Mechanics ; Therapy</subject><ispartof>Journal of materials science, 2020-06, Vol.55 (16), p.6992-7008</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>COPYRIGHT 2020 Springer</rights><rights>Journal of Materials Science is a copyright of Springer, (2020). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-db7272aaf0fb22d96cef0ce7b34e2093431ca17fa6b867754c6189bc3e9c67203</citedby><cites>FETCH-LOGICAL-c420t-db7272aaf0fb22d96cef0ce7b34e2093431ca17fa6b867754c6189bc3e9c67203</cites><orcidid>0000-0003-0506-1876</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10853-020-04495-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10853-020-04495-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids></links><search><creatorcontrib>Hu, Hang</creatorcontrib><creatorcontrib>Wang, Chong</creatorcontrib><creatorcontrib>Zhang, Rong</creatorcontrib><creatorcontrib>Xiao, Chen</creatorcontrib><creatorcontrib>Lai, Chao</creatorcontrib><creatorcontrib>Li, Zifu</creatorcontrib><creatorcontrib>Xu, Defeng</creatorcontrib><title>Branched worm-like nanoparticles featured with programmed drug release for synergistic castration-resistant prostate cancer therapy</title><title>Journal of materials science</title><addtitle>J Mater Sci</addtitle><description>Co-delivery systems with programmed release of combined drugs are of great value for combination cancer therapy. However, design of such co-delivery systems for potent synergistic cancer therapy is still a great challenge. In the present work, dimethylcurcumin (DMC) and docetaxel (DTX) co-loaded branched worm-like nanoparticles (NPs) with programmed release of DMC and DTX were developed for potent synergistic castration-resistant prostate cancer (CRPC) therapy. (2-Hydroxypropyl)-β-cyclodextrin-retinoic acid (HP-β-CD-RA) conjugates with different molar ratios of RA to HP-β-CD were synthesized and used for the preparation of DMC and DTX co-loaded NPs. The as-prepared DMC and DTX co-loaded NPs (
D
h
170–190 nm) have branched worm-like morphologies, and DMC/DTX@HP-β-CD-RA
3.0
NPs show the highest drug loading content and encapsulation efficiency. DMC/DTX@HP-β-CD-RA
3.0
NPs exhibit programmed drug release patterns with DTX released much faster than DMC, which could be ascribed to the difference between DMC and DTX in the interaction with HP-β-CD-RA
3.0
as analyzed by molecular simulation, phase solubility method, and fluorescence spectra. DMC/DTX@HP-β-CD-RA
3.0
NPs exhibit enhanced cellular uptake as compared to DMC/DTX. Mechanism dissection reveals that the cellular uptake of DMC/DTX@HP-β-CD-RA
3.0
NPs is energy-dependent in which macropinocytosis and clathrin- and caveolae-independent endocytosis pathways are involved. Benefited from their enhanced cellular uptake and programmed drug release, DMC/DTX@HP-β-CD-RA
3.0
NPs exhibit significantly enhanced antitumor effect as compared to DMC/DTX. Such mechanisms for potent synergistic antitumor effect, by enhancing cellular uptake of DMC and DTX together with programmed drug release, may provide new therapeutic options for CRPC.</description><subject>Anticancer properties</subject><subject>Cancer therapies</subject><subject>Characterization and Evaluation of Materials</subject><subject>Chemistry and Materials Science</subject><subject>Classical Mechanics</subject><subject>Crystallography and Scattering Methods</subject><subject>Cyclodextrins</subject><subject>Drug delivery systems</subject><subject>Fluorescence</subject><subject>Health aspects</subject><subject>Materials for Life Sciences</subject><subject>Materials Science</subject><subject>Morphology</subject><subject>Nanoparticles</subject><subject>Polymer Sciences</subject><subject>Prostate cancer</subject><subject>Retinoic acid</subject><subject>Solid Mechanics</subject><subject>Therapy</subject><issn>0022-2461</issn><issn>1573-4803</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9kUuLFDEURgtRsB39A64KXLnIePOoStdyHHwMDAg-1iGVuqnOWJVqb1KMvfaPm7aFoUEkiyQ35-T1VdVLDpccQL9JHLaNZCCAgVJdw7pH1YY3WjK1Bfm42gAIwYRq-dPqWUp3ANBowTfVr7dko9vhUN8vNLMpfMc62rjsLeXgJky1R5tXOgIh7-o9LSPZeS7zgdaxJpzQJqz9QnU6RKQxpCLWzqZMNoclMsJUajbmo1wGGctqdEh13iHZ_eF59cTbKeGLv_1F9e39u6_XH9ntpw8311e3zCkBmQ29FlpY68H3Qgxd69CDQ91LhQI6qSR3lmtv237bat0o1_Jt1zuJnWu1AHlRvTrtW-7xY8WUzd2yUixHGiF10zadbJoHarQTmhD9Uh7i5pCcuWq5BiVbeaQu_0GVNuAc3BLRh1I_E16fCYXJ-DOPdk3J3Hz5fM6KE-vKhyVCb_YUZksHw8Ec8zanvE3J2_zJ23RFkicpFTiOSA-v-4_1G1Vnrto</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Hu, Hang</creator><creator>Wang, Chong</creator><creator>Zhang, Rong</creator><creator>Xiao, Chen</creator><creator>Lai, Chao</creator><creator>Li, Zifu</creator><creator>Xu, Defeng</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>8FE</scope><scope>8FG</scope><scope>ABJCF</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>HCIFZ</scope><scope>KB.</scope><scope>L6V</scope><scope>M7S</scope><scope>PDBOC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><orcidid>https://orcid.org/0000-0003-0506-1876</orcidid></search><sort><creationdate>20200601</creationdate><title>Branched worm-like nanoparticles featured with programmed drug release for synergistic castration-resistant prostate cancer therapy</title><author>Hu, Hang ; Wang, Chong ; Zhang, Rong ; Xiao, Chen ; Lai, Chao ; Li, Zifu ; Xu, Defeng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-db7272aaf0fb22d96cef0ce7b34e2093431ca17fa6b867754c6189bc3e9c67203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Anticancer properties</topic><topic>Cancer therapies</topic><topic>Characterization and Evaluation of Materials</topic><topic>Chemistry and Materials Science</topic><topic>Classical Mechanics</topic><topic>Crystallography and Scattering Methods</topic><topic>Cyclodextrins</topic><topic>Drug delivery systems</topic><topic>Fluorescence</topic><topic>Health aspects</topic><topic>Materials for Life Sciences</topic><topic>Materials Science</topic><topic>Morphology</topic><topic>Nanoparticles</topic><topic>Polymer Sciences</topic><topic>Prostate cancer</topic><topic>Retinoic acid</topic><topic>Solid Mechanics</topic><topic>Therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hu, Hang</creatorcontrib><creatorcontrib>Wang, Chong</creatorcontrib><creatorcontrib>Zhang, Rong</creatorcontrib><creatorcontrib>Xiao, Chen</creatorcontrib><creatorcontrib>Lai, Chao</creatorcontrib><creatorcontrib>Li, Zifu</creatorcontrib><creatorcontrib>Xu, Defeng</creatorcontrib><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Technology Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>SciTech Premium Collection</collection><collection>Materials Science Database</collection><collection>ProQuest Engineering Collection</collection><collection>Engineering Database</collection><collection>Materials Science Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><jtitle>Journal of materials science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hu, Hang</au><au>Wang, Chong</au><au>Zhang, Rong</au><au>Xiao, Chen</au><au>Lai, Chao</au><au>Li, Zifu</au><au>Xu, Defeng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Branched worm-like nanoparticles featured with programmed drug release for synergistic castration-resistant prostate cancer therapy</atitle><jtitle>Journal of materials science</jtitle><stitle>J Mater Sci</stitle><date>2020-06-01</date><risdate>2020</risdate><volume>55</volume><issue>16</issue><spage>6992</spage><epage>7008</epage><pages>6992-7008</pages><issn>0022-2461</issn><eissn>1573-4803</eissn><abstract>Co-delivery systems with programmed release of combined drugs are of great value for combination cancer therapy. However, design of such co-delivery systems for potent synergistic cancer therapy is still a great challenge. In the present work, dimethylcurcumin (DMC) and docetaxel (DTX) co-loaded branched worm-like nanoparticles (NPs) with programmed release of DMC and DTX were developed for potent synergistic castration-resistant prostate cancer (CRPC) therapy. (2-Hydroxypropyl)-β-cyclodextrin-retinoic acid (HP-β-CD-RA) conjugates with different molar ratios of RA to HP-β-CD were synthesized and used for the preparation of DMC and DTX co-loaded NPs. The as-prepared DMC and DTX co-loaded NPs (
D
h
170–190 nm) have branched worm-like morphologies, and DMC/DTX@HP-β-CD-RA
3.0
NPs show the highest drug loading content and encapsulation efficiency. DMC/DTX@HP-β-CD-RA
3.0
NPs exhibit programmed drug release patterns with DTX released much faster than DMC, which could be ascribed to the difference between DMC and DTX in the interaction with HP-β-CD-RA
3.0
as analyzed by molecular simulation, phase solubility method, and fluorescence spectra. DMC/DTX@HP-β-CD-RA
3.0
NPs exhibit enhanced cellular uptake as compared to DMC/DTX. Mechanism dissection reveals that the cellular uptake of DMC/DTX@HP-β-CD-RA
3.0
NPs is energy-dependent in which macropinocytosis and clathrin- and caveolae-independent endocytosis pathways are involved. Benefited from their enhanced cellular uptake and programmed drug release, DMC/DTX@HP-β-CD-RA
3.0
NPs exhibit significantly enhanced antitumor effect as compared to DMC/DTX. Such mechanisms for potent synergistic antitumor effect, by enhancing cellular uptake of DMC and DTX together with programmed drug release, may provide new therapeutic options for CRPC.</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s10853-020-04495-9</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0003-0506-1876</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-2461 |
| ispartof | Journal of materials science, 2020-06, Vol.55 (16), p.6992-7008 |
| issn | 0022-2461 1573-4803 |
| language | eng |
| recordid | cdi_proquest_journals_2375659355 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Anticancer properties Cancer therapies Characterization and Evaluation of Materials Chemistry and Materials Science Classical Mechanics Crystallography and Scattering Methods Cyclodextrins Drug delivery systems Fluorescence Health aspects Materials for Life Sciences Materials Science Morphology Nanoparticles Polymer Sciences Prostate cancer Retinoic acid Solid Mechanics Therapy |
| title | Branched worm-like nanoparticles featured with programmed drug release for synergistic castration-resistant prostate cancer therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T03%3A11%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Branched%20worm-like%20nanoparticles%20featured%20with%20programmed%20drug%20release%20for%20synergistic%20castration-resistant%20prostate%20cancer%20therapy&rft.jtitle=Journal%20of%20materials%20science&rft.au=Hu,%20Hang&rft.date=2020-06-01&rft.volume=55&rft.issue=16&rft.spage=6992&rft.epage=7008&rft.pages=6992-7008&rft.issn=0022-2461&rft.eissn=1573-4803&rft_id=info:doi/10.1007/s10853-020-04495-9&rft_dat=%3Cgale_proqu%3EA617043635%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2375659355&rft_id=info:pmid/&rft_galeid=A617043635&rfr_iscdi=true |